Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease

• Published in: Advances in therapy 2017-08, Vol.34 (8), p.2007-2021
• Main Authors: Strong, Heather, Mitchell, Monica J., Goldstein-Leever, Alana, Shook, Lisa, Malik, Punam, Crosby, Lori E.
• Format: Article
• Language: English
• Subjects: Adult; Age Factors; Aged; Anemia, Sickle Cell - therapy; Attitude to Health; Cardiology; Cell- and Tissue-Based Therapy; Endocrinology; Female; Focus Groups; Gene Transfer Techniques; Health Knowledge, Attitudes, Practice; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Research; Patient Education as Topic; Pharmacology/Toxicology; Rheumatology; Young Adult
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-017-0587-7

Introduction Sickle cell disease (SCD) is a chronic genetic disease with high morbidity and early mortality; it affects nearly 100,000 individuals in the USA. Bone marrow transplantation, the only curative treatment, is available to less than 20% of patients because of a number of access barriers. Gene transfer therapy (GTT) has been shown to be curative in animal models and is approved for use in humans for early-phase studies at a few centers. GTT would offer a more accessible treatment option available to all patients. It is important to understand patient perspectives on GTT to help ensure human clinical trial success. Methods Two focus groups were conducted with younger (18–30 years) and older (31 years and older) adults with SCD to obtain data on patient knowledge and beliefs about GTT. Data from these two focus groups was used to develop a GTT educational brochure. A third focus group was conducted to obtain participant feedback on acceptability and feasibility of education and the brochure. Results Most adults, especially young adults, had little knowledge about GTT and expressed fear and uncertainty about the side effects of chemotherapy (e.g., hair loss, infertility), use of a human immunodeficiency virus (HIV)-derived viral vector, and potential for cancer risk. Participants wanted full transparency in educational materials, but advised researchers not to share the vector’s relation to HIV because of cultural stigma and no HIV virus is used for the GTT vector. Conclusion Older adults had more desire to participate in human clinical GTT trials than younger participants. When recruiting for trials, researchers should develop GTT educational materials that address participant lack of trust in the healthcare system, cultural beliefs, fears related to side effects, and include visual illustrations. Use of such materials will provide adults with SCD the information they need to fully evaluate GTT.